Compare MKTX & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MKTX | MMED |
|---|---|---|
| Founded | 2000 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.7B |
| IPO Year | 2004 | 2025 |
| Metric | MKTX | MMED |
|---|---|---|
| Price | $165.22 | $18.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $162.22 | $25.33 |
| AVG Volume (30 Days) | 769.3K | ★ 8.6M |
| Earning Date | 10-23-2026 | 11-24-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.66 | N/A |
| Revenue | $397,471,000.00 | ★ $3,102,000,000.00 |
| Revenue This Year | $5.07 | $10.76 |
| Revenue Next Year | $6.86 | $8.51 |
| P/E Ratio | $29.18 | ★ N/A |
| Revenue Growth | 7.45 | ★ 14.25 |
| 52 Week Low | $108.75 | $10.65 |
| 52 Week High | $195.97 | $24.43 |
| Indicator | MKTX | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 60.12 | 47.68 |
| Support Level | $164.25 | $16.61 |
| Resistance Level | $165.83 | $20.40 |
| Average True Range (ATR) | 0.34 | 0.95 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 56.02 | 45.31 |
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy. Medtronic acquired MiniMed in 2001 and then spun it out in 2026 (though Medtronic still owns roughly 90% of MiniMed shares, which will be relayed to its shareholders as a tax-free distribution in the foreseeable future). MiniMed is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables.